By combining 20 years of method development and validation experience and advance instrumentation, BRI supports clinical PK, pre-clinical TK/PK, rapid PK screening and BA/BE studies through automation using Thermo Scientific Watson (LIMS). Every assay is validated based on a protocol-driven…
MoreThe use of in vitro assays to define drug metabolism in animals and humans prior to in vivo studies is a pivotal step in defining the drug-like properties of new drug candidates. BRI provides in vitro drug candidate metabolism screening, metabolite characterization, induction, inhibition and ADMET…
MoreIn addition to traditional mouse PK studies, BRI also offers dried blood spot (DBS) sampling technique to allow serial sampling collection of whole blood from a mouse over the entire PK profile. The same technique also applies in xenograft mouse…
MoreBRI offers a variety of analytical chemistry assays supporting API/clinical product quality control and IND-enabling stability studies conducted in conformance to GMP and ICH requirements. QUALITY CONTROL IND-Enabling API / Clinical Product Quality Control Assays – Manufacturing specification release assays – Complementary LC/MS, HPLC and GC…
MoreLed by a group of expert scientists, BRI involves in the following areas of cancer drug discovery and development activities: – Cancer molecular target genetic screening – Cancer cell biology and pharmacology – Patient-derived orthotopic subrenal capsule xenograft mouse model development – Unique…
More